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ess: Frank.ReichenbergSummary Nebulised iloprost is established therapy of severe pulmonary hyperten-
sion; however, the effects on the bronchoalveolar compartment have not been
investigated so far. We studied the short- and long-term effects of nebulised iloprost
on pulmonary function tests and gas exchange in 63 patients with severe pulmonary
hypertension (idiopathic n ¼ 17, chronic thromboembolism n ¼ 15, connective
tissue disease n ¼ 12, congenital heart disease n ¼ 11, respiratory diseases n ¼ 8).
Patients received iloprost in increasing dose up to 140 mg iloprost/24 h via an
ultrasonic nebuliser.
Short-term effects were assessed before and after every nebulisation: peak
expiration flow decreased in mean by 1.9% (423798 to 415798) and percutaneous
oxygen saturation increased in mean by 0.7% (9076 to 9175) post-nebulisation.
There were no significant differences concerning underlying diagnosis or dose of
nebulised iloprost. Within 3 months, 9 patients stopped treatment due to non-
compliance with frequent nebulisations (n ¼ 3), or severe side effects (n ¼ 4); 2
patients with additional obstructive lung disease developed bronchoconstriction.
Long-term effects were assessed by pulmonary function tests and gas exchange
parameters at baseline and after 3 months treatment. There were no significant
differences after 3 months therapy neither in FEV1, FVC, TLC, residual volume nor in
diffusions capacity, SO2 at rest and during 6min walking test, also in respect of the
underlying diseases. However, there was a significant increase in 6min walking
distance (6 MWD) after 3 months (2467113 to 2947115m, Po0.05).
In conclusion, treatment with nebulised iloprost leads to functional improvement
in severe pulmonary hypertension without systematic adverse short- and long-term
effects on pulmonary function test or gas exchange. Patients with additionalElsevier Ltd. All rights reserved.
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F. Reichenberger et al.218obstructive lung disease might develop bronchoconstriction. Severe side effects
leading to discontinuation of treatment occurred in 9% of patients.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Nebulised iloprost is established in the therapy of
pulmonary hypertension of different origin leading
to a significant symptomatic, functional and hae-
modynamic improvement.1 The nebulised applica-
tion of prostanoid has the advantage of pulmonary
selectivity leading to fewer systemic side effects
and improved ventilation–perfusion ratio in the
lung, in particular important in patients with
underlying pulmonary parenchymal disorder.2,3
However, possible intrabronchial effects during
nebulisation have not been investigated so far.
Patients with pulmonary hypertension have an
impaired gas exchange at rest and during exercise
leading to an impaired oxygenation.4 Furthermore,
bronchial changes with peripheral airways obstruc-
tion have been described in patients with primary
pulmonary hypertension.5
Previous in vitro and in vivo studies of prosta-
noids in the bronchial compartment showed vari-
able results. While some authors describe a
bronchodilating activity of iloprost and prostacyclin
in vivo and in vitro,6,7 other describe opposite
results of inhaled prostacyclin in vivo,8 and one
report described bronchoconstrictive effects of
inhaled prostacyclin in asthmatics.9
Published studies on treatment with nebulised
iloprost, using a range of 37.5–130mg daily iloprost
dose and different nebulisers, reported typical side
effect as nausea, cough, flush, chest pain, and jaw
pain. However, in none of these studies bronchoal-
veolar side effects have been further analysed.1,10–13
Therefore, we evaluated the short- and long-
term effects of nebulised iloprost on pulmonary
function tests and pulmonary gas exchange in
patients, who were newly commenced on nebulised
iloprost therapy for treatment of severe pulmonary
hypertension of different origin.Patients and methods
We included 63 patients (28 male, 37 female, mean
age 48 (16–83) years) with severe pulmonary
hypertension or different origin. In total, 17
patients suffered from idiopathic pulmonary arter-
ial hypertension (IPAH); 15 patients had chronic
thromboembolic pulmonary hypertension (CTEPH),
among them 6 patients with proximal vascularobstructions amenable for pulmonary thromben-
darterectomy. In 12 patients, pulmonary arterial
hypertension has been associated with connective
tissue disease (CTD), and in 11 patients pulmonary
arterial hypertension developed due to congenital
heart disease (CHD). In 8 patients, pulmonary
hypertension was associated with respiratory dis-
eases (RD), among them 3 patients with idiopathic
pulmonary fibrosis on chronic immuno-modulating
therapy requiring long-term oxygen therapy, and 5
patients with COPD and emphysema in GOLD IV due
to right heart failure despite treatment with
oxygen supplementation, inhaled bronchodilators
and diuretics.14
Patients underwent pulmonary function tests,
6min walking test with measurement of percuta-
neous oxygen saturation, and right heart catheter-
isation with Swanz-Ganz Catheter including
measurement of cardiac output by thermodilution
method at baseline and after 3 months therapy. At
the follow-up 6min walking test (6 MWT) and
haemodynamic measurements and were performed
at least 2 h after last iloprost inhalation.
After baseline examinations, all patients were
newly started on treatment with nebulised iloprost
using an ultrasonic jet nebuliser (Multisonic com-
pacts, Schill Company, Germany) with an efficacy
of 86%.10
A dose of 20 mg iloprost was dissolved in 3mls
normal saline. This stock has been further diluted
to obtain fluid samples of 3ml containing approxi-
mately 3.3, 6.6, 9.9, 13.2, 16.5 or 20 mg iloprost.
Patients nebulised the iloprost solution over
5–8min every 3 h with a night time break. The
dose was gradually increased from approximately
3.3 mg up to a maximum dose of 20 mg/nebulisation
over a period of 1 week in respect to the patients
symptoms.
Finally, all patients received 7 nebulisations per
day with a total dose of 140 mg/24 h consistent with
a mouthpiece dose of 120 mg/24 h.
Short-term effects were assessed using peak
expiration flow (PEF) (best of 3 readings) and
percutaneous oxygen saturation (SO2) measured
before and after every nebulisation. Results were
analysed as the mean change of either PEF or SO2
after nebulisation in respect to the underlying
disease and the dose of iloprost nebulised.
Long-term effects on pulmonary function and gas
exchange were assessed by using spirometry and
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many) with analysis of forced expiratory volume in
1 s (FEV1), forced vital capacity (FVC), total lung
capacity (TLC), and residual volume (RV). The ratio
between RV and TLC has been used as surrogate
parameter for small airway function.15,16
Values are expressed as percent predicted using
the reference values of the European Society for
Coal and Steal (ESCS).
Gas exchange was assessed by measurement of
diffusion capacity (Keogh factor) using the CO-
single breath method corrected for haemoglobin
and alveolar volume (Jaegers, Wuerzburg, Ger-
many). Furthermore, we measured SO2 at rest and
minimum SO2 during 6min walking test (6MWT) as a
sensitive parameter for exercise induced distur-
bance in gas exchange.17 Results were expressed as
mean change after 3 months from baseline and
analysed concerning underlying disease.
As data were normally distributed, results are
expressed in mean (7standard deviation). Analysis
for statistically significant differences was per-
formed using paired t-test.Results
Short-term effects were analysed in all 65 patients
with a mean pre- nebulisation PEF of 423798 andTable 1 Mean PEF before and after nebulisation in resp
PEF (pre) PEF (post) Cha
PEF
Total (n ¼ 63) 423 (98) 415 (98) 1.
IPAH (n ¼ 17) 406 (89) 400 (89) 1.
CTEPH (n ¼ 15) 406 (90) 397 (95) 2.
CTD (n ¼ 12) 412 (102) 407 (103) 1.
CHD (n ¼ 11) 409 (103) 397 (103) 2.
RD (n ¼ 8) 411 (113) 413 (112) +0.
For abbreviations see text.
Table 2 Mean PEF before and after nebulisation in resp
Dose per nebulisation
(mg)
PEF (pre) PEF (post) Cha
PEF
3.3 412 (108) 407 (103) 1.
6.6 423 (100) 415 (102) 1.
9.9 438 (97) 427 (101) 2.
13.2 429 (101) 417 (101) 2.
15 420 (100) 414 (100) 1.
20 415 (80) 407 (80) 1.
For abbreviations see text.mean post nebulisation of PEF 415798 with a mean
change of 1.9%. There were no clinically or
statistically significant differences concerning the
underlying diagnoses or the iloprost dosage (Tables
1 and 2). Mean SO2 before nebulisation was 9076%
and after nebulisation 9175% with a mean change
of +0.7% without clinically or statistically signifi-
cant differences concerning the underlying diag-
noses or the iloprost dosages (Tables 1 and 2).
Among the study population, 23 patients pre-
sented with an obstructive pattern in pulmonary
function tests displayed by an FEV1/FVC ratioo70%
according to the GOLD criteria.14 In these patients,
mean PEF decreased by 1.7% from 336 (81) to 331
(84), whereas SO2 changed by +2.0% from 87 (7) to
89 (5)%. During initiation of therapy the majority of
patients experienced typical side effects including
flushing, headaches, jaw pain, nausea, and leg
cramps, which disappeared during continuous
therapy.
Within the first 3 months of treatment, 15
patients stopped treatment with nebulised ilo-
prost, among them 4 patients due to persistent
and severe side effects, especially headaches and
nausea during initiation phase of treatment despite
dose reduction. Three patients were non-compliant
with frequent nebulisations. Two patients devel-
oped severe dyspnoea and wheezing due to
bronchoconstriction after 2 and 4 weeks afterect of the underlying diagnoses in mean (SD).
nge
(%)
SO2 (pre) SO2 (post) Change
SO2 (%)
9 90 (6) 91 (5) +0.7
6 92 (5) 92 (6) +0.6
2 93 (2) 92 (2) 0.9
3 89 (5) 90 (4) +1.9
7 84 (7) 87 (5) +3.0
4 88 (5) 89 (5) +0.9
ect of the dose of the iloprost dose in mean (SD).
nge
(%)
SO2 (pre) SO2 (post) Change
SO2 (%)
3 89 (7) 90 (6) 1.3
8 89 (6) 90 (5) 0.8
5 90 (6) 91 (5) 0.8
7 90 (7) 91 (5) 0.6
4 90 (6) 91 (5) 0.9
8 91 (5) 91 (4) 0.1
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after stop of nebulisations. Six patients underwent
pulmonary thromboendarterectomy for CTEPH and
received nebulised iloprost as bridging to surgery.
Forty-eight patients completed the 3 months
follow up including repeat PFT, 6 MWT and right
heart catheterisation. There was a significant
increase in 6min walking distance from 2467113
to 2947115m; however no significant change in
resting haemodynamics. The increase in functionalTable 3 Functional and haemodynamic change
on treatment with nebulised iloprost in the subset
of 48 patients completing the 3 months followup
mean (SD).
Baseline 3 months
RAP (mmHg) 9 (6) 10 (7)
mPAP (mmHg) 56 (13) 55 (14)
CI (l/min/qm) 1.9 (0.6) 2.1 (0.5)
TPR (dyn s cm5) 1225 (348) 1124 (349)
CVSO2 (%) 62 (8) 60 (8)
6 MWD (m) 246 (113) 294 (115)
RAP—right atrial pressure, mPAP—mean pulmonary ar-
tery pressure, CI—cardiac index, TPR—total pulmonary
resistance, CVSO2—central venous saturation, 6
MWD—6min walking distance.
Paired t-test Po0.05.
Table 4 PFTat baseline (BL) as % predicted, and change
patients, mean (SD).
FEV1
(BL)
Change
(%)
FVC
(BL)
Change
(%)
TL
(B
Total (n ¼ 48) 74 (20) 0.2 86 (24) +1.3 93
PPH (n ¼ 17) 76 (17) +2.4 90 (24) +2.4 93
CTEPH (n ¼ 7) 79 (17) +4.5 92 (18) +9.1 93
CTD (n ¼ 12) 78 (24) 0.8 81 (24) +1.3 90
CHD (n ¼ 8) 72 (20) 1.2 83 (23) +0.9 94
RD (n ¼ 4) 60 (27) +4.4 80 (41) +6.8 90
For abbreviations see text.
Table 5 Gas exchange at baseline (BL) as % predicted,
iloprost in 48 patients, mean (SD).
KCO (BL) Change (%) Rest SO2
Total (n ¼ 48) 70 (23) 1.9 92 (6)
PPH (n ¼ 17) 68 (19) 1.0 94 (4)
CTEPH (n ¼ 7) 87 (16) +7.2 94 (3)
CTD (n ¼ 12) 57 (20) 3.4 94 (3)
CHD (n ¼ 8) 84 (19) 3.4 87 (7)
RD (n ¼ 4) 41 (5) 4.1 90 (5)
KCO—Keogh factor, rest SO2—resting SO2, walk SO2—minimum Scapacity was detected in all subgroups of patients.
Data are shown in Tables 3 and 7.
At baseline, mean FEV1 and FCV were reduced
with 747720% pred. and 86724% pred., respec-
tively. The mean FEV1/FVC ratio was 86%. Mean TLC
was marginally reduced with 93718% pred.,
whereas the RV was increased by 114724% pred.
After 3 months treatment, there was a change of
mean FEV1 of 0.2%, mean FVC of +1.3%, mean TLC
of +2.5%, and mean RV of +3.9%. Ratio of RV/TLC as
surrogate parameter for small airway dysfunction
was normal with 40% at baseline with minimal
change after 3 months treatment.
There were no statistically significant differences
in the whole study population as well as the
different diagnoses groups. Details are shown in
Table 4.
Concerning gas exchange, Keogh factor at base-
line was reduced at 70723% pred., as well as SO2 at
rest with 9276%, and minimum. SO2 during 6 MWT
with 83712%. After 3 months treatment there was
a mean change in Keogh factor by 1.9%. SO2 at
rest changed in mean by +1.7%. Assessing the
minimum SO2 during 6 MWT, there was a mean
change of +0.1% after 3 months. Details are shown
in Table 5. There were no statistically significant
differences in the whole study population as well as
the different diagnoses groups comparing baseline
and 3 months follow-up parameters.after 3 months treatment with nebulised iloprost in 48
C
L)
Change
(%)
RV
(BL)
Change
(%)
RV/TLC
(BL)
Change
(%)
(18) +2.5 114 (24) +3.9 41 (8) +2.4
(17) +4.1 113 (20) +6.0 39 (7) +3.4
(18) 4.3 107 (28) +6.3 40 (9) +3.5
(18) 6.4 109 (25)3.3 41 (8) +4.1
(19) +5.0 123 (22) +4.4 43 (11) 2.1
(25) +4.2 114 (27) +4.6 46 (9) 4.0
and change after 3 months treatment with nebulised
(BL) Change (%) Walk SO2 (BL) Change (%)
+1.7 83 (12) +0.1
+0.2 86 (11) 0.6
+2.5 90 (4) +0.7
+0.3 85 (9) +1.1
+4.6 73 (13) +1.3
+5.1 80 (13) +7.6
O2 during 6min walk test, for other abbreviations see text.
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Nebulised iloprost on pulmonary function 221Discussion
In this study, we found neither short- nor long-term
systematic adverse effects on pulmonary function
test or gas exchange in patients with pulmonary
hypertension of different origin. Two patients with
underlying obstructive lung disease developed
broncoconstriction on treatment with nebulised
iloprost with recovery after cessation of therapy,
accounting for about 9% of patients with underlying
obstructive lung disease in our series. As any
inhaled compound may provoke bronchial irritant
effects, especially in these patients a routine
pulmonary function testing should be performed
at follow-up.
At baseline patients presented with a slight
reduction in lung volumes, consistent with a recent
report about impaired peripheral airway function in
patients with primary pulmonary hypertension.5 In
long-term follow-up, there were no significant
changes in FEV1, FVC, TLC and RV indicating no
significant obstructive or restrictive changes, or
hyperinflation.18,19
For assessment of gas exchange, we used mini-
mum SO2 before and after inhalation for easy and
rapid assessment of short-term effects on oxygena-
tion. For long-term changes the CO-diffusion
capacity corrected for alveolar volume and hae-
moglobin was used as the most sensitive and
comprehensive parameter. Furthermore, minimum
SO2 during 6MWT reflects oxygenation status during
exercise.17,18 Our data indicate that nebulised
iloprost is not associated with short- or long-term
adverse effect on pulmonary gas exchange in
patients with pulmonary hypertension of different
origin. There was a tendency toward better SO2 at
rest and during exercise in the RD group, however
this was not statistically significant (Table 5).
Only in one study in patients with pulmonary
hypertension due to lung fibrosis there was an
insignificant reduction of SaO2 after acute inhala-
tion of prostacyclin.3
In our study, 3 months treatment resulted in a
significant increase in 6 MWD of 48m in the whole
study population, comparable to the result of the
randomised controlled trial on nebulised iloprost in
pulmonary hypertension with a mean increase in 6
MWD of 36m after 3 months treatment.1
Treatment with nebulised iloprost demands a
commitment, as 7 nebulisations per day are
required, and compliance problems are inevita-
ble.18 So far, data concerning compliance with
treatment and severity of side effects in chronic
use of nebulised iloprost are sparse. Typically, side
effects occur pronounced during initiation phase of
therapy.1,11,12,20
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Table 7 Change in 6min walking distance after 3
month’s treatment according to origin of pulmon-
ary hypertension (only patient who completed
followup are enclosed).
Baseline 3 months
IPAH (n ¼ 17) 300 (105) 333 (133)
CTEPH (n ¼ 7) 227 (130) 282 (96)
CTD (n ¼ 12) 220 (81) 274 (67)
CHD (n ¼ 8) 272 (110) 300 (124)
RD (n ¼ 4) 220 (49) 260 (63)
Total (n ¼ 48) 246 (113) 294 (115)
F. Reichenberger et al.222In our study, 3 patients stopped treatment due to
non-compliance (4%). Furthermore, 4 patients
stopped treatment due to severity of side effects
during initiation of therapy (6%). This might be
contributed by the relatively high dose of iloprost
used, although appropriate dose reduction has
been attempted in these patients. Concerning
subgroup analysis, 50% of patients in the RD group
stopped treatment due to side effects, and all of
them had underlying COPD. Therefore, side effects
due to probable airway irritation should be con-
sidered in these patients. (Tables 6 and 7).
In total, 9 patients stopped treatment due to
iloprost related side effects or non-compliance
with frequent nebulisations (14%).
In conclusion, nebulised iloprost is an effective
treatment in pulmonary hypertension of different
origin without systematic adverse effects on
pulmonary function test and gas exchange. A
bronchoconstrictive effect might develop in pa-
tients with underlying obstructive lung disease. In
our study, 14% of patients stopped treatment due to
side effects or non-compliance.References
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